Camzyos (mavacamten)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- mavacamten
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Authorised
- Therapeutic area
- Cardiomyopathy, Hypertrophic
- EU approval
- Mon 26 Jun 2023
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005457
- ATC
- C01EB
- Official record
- www.ema.europa.eu
Indication
Treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Regulatory milestones
No milestones recorded in the last year.
Follow Camzyos
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.